Bluejay Investor Presentation Deck

Symphony™M IL-6 Potential Clinical Advantages v. Current Standard Tests Metric Area Under Receiver Operator Characteristic Curve (AUC) Youden Index Cutoff Sensitivity Specificity NPV 00 Interleukin-6 (IL-6) 0.801 DIAGNOSTICS 1.52 35 pg/mL 0.89 (0.65, 0.99) 0.64 (0.55, 0.72) 0.98 (0.92, 1.00) C-Reactive Protein (CRP) 0.578 1.35 113.95 mg/mL 0.44 (0.22, 0.69) 0.91 (0.84, 0.95) 0.92 (0.86, 0.96) Lactate 0.680 1.29 1.75 mmol/L 0.56 (0.31, 0.78) 0.74 (0.61, 0.84) 0.85 (0.72, 0.93) Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Sensitivity 1.0 0.8- 0.6- 0.4 0.2- 0.0- T 1.0 ROC Curves of Biomarker Prediction of IMV 0.8 0.6 IL-6 (AUC = 0.801) CRP (AUC = 0.578) Lactate (AUC = 0.680) 0.4 Specificity An analysis of the Bluejay's clinical study assessing the ability of Symphony IL-6 at time of hospital admission to predict patients at risk for invasive mechanical ventilation (IMV) during their hospitalization demonstrated favorable clinical performance with a sensitivity of 89%, specificity of 64%, and negative predictive value of 98%, highlighting the potential higher clinical utility of IL-6 compared to these other standard biomarkers to identify patients at future risk of IMV. 0.2 0.0 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 9

View entire presentation